Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma

Gemcitabine and cisplatin serve as appropriate treatments for patients with cholangiocarcinoma (CCA). Our previous study using histoculture drug response assay (HDRA), demonstrated individual response patterns to gemcitabine and cisplatin. The current study aimed to identify predictive biomarkers fo...

Descripción completa

Detalles Bibliográficos
Autores principales: Suksawat, Manida, Phetcharaburanin, Jutarop, Klanrit, Poramate, Namwat, Nisana, Khuntikeo, Narong, Titapun, Attapon, Jarearnrat, Apiwat, Vilayhong, Vanlakhone, Sa-ngiamwibool, Prakasit, Techasen, Anchalee, Wangwiwatsin, Arporn, Mahalapbutr, Panupong, Li, Jia V., Loilome, Watcharin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Public Health
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866176/
https://www.ncbi.nlm.nih.gov/pubmed/35223723
http://dx.doi.org/10.3389/fpubh.2022.766023

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8866176/
https://www.ncbi.nlm.nih.gov/pubmed/35223723
http://dx.doi.org/10.3389/fpubh.2022.766023

Ejemplares similares